Recruiting Clinical Trials

Displaying 161 - 170 of 242 result(s)
Study Title Condition Phase Location
A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Pat ... Non Alcoholic Steatohepatitis (NASH) Phase 2
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Belgium
  • Country: 
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Patients With Symptomatic COVID-19 - The "EMPATHY" Trial COVID-19 Phase 2, Phase 3
  • Country: 
    India
An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomog ... Amyotrophic Lateral Sclerosis Phase 2
  • Country: 
    United States
  • Country: 
    Finland
  • Country: 
    Sweden
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation Chronic Myelogenous Leukemia - Chronic Phase Phase 3
  • Country: 
    United States
An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of LNP023 in Subjects With C3 Glomerulopathy C3 Glomerulopathy Phase 2
  • Country: 
    France
  • Country: 
    Italy
  • Country: 
    Spain
A Phase 3b, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors. Chronic Myelogenous Leukemia Phase 3
  • Country: 
    Austria
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib ALK Positive Malignancies Phase 4
  • Country: 
    Belgium
  • Country: 
    Brazil
  • Country: 
    China
  • Country: 
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-pos ... Differentiated Thyroid Cancer Phase 3
  • Country: 
    China
  • Country: 
    India
  • Country: 
    Korea, Republic of
  • Country: 
A Phase II, Randomized (1:1) Open Label Study to Assess the Efficacy and Safety of Eltrombopag in Combination With Dexamethasone Compared to Dexamethasone, as First-line Treatment in Adult Patients With Newly Diagnosed Immune Thrombocytopenia Immune Thrombocytopenia (ITP) Phase 2
  • Country: 
    Germany
A Randomized, Double-blind, Placebo-controlled, Japan Local Phase II Clinical Study Comparing Eltrombopag Monotherapy Versus Placebo in Adult Lower-risk Myelodysplastic Syndromes (MDS) Patients With Platelet Transfusion Dependence Myelodysplastic Syndromes Phase 2
  • Country: 
    Japan